Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2025 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address...
March 19, 2025 07:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial...
March 18, 2025 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:...
March 17, 2025 18:55 ET | Source: Cygnus Metals Ltd

Strong drilling results point to growth and upgrades in copper-gold resource

TORONTO and PERTH, Western Australia, March 17, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS: Cygnus’ strategy to create shareholder value by growing the overall Chibougamau Resources and upgrading more...
March 17, 2025 09:05 ET | Source: PacBio

Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in...
March 13, 2025 16:10 ET | Source: Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
March 13, 2025 10:05 ET | Source: Miracle Recreation

New Interactive Musical Play Space Opens at Cain Center for the Arts

CORNELIUS, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- Make An Impact Foundation, the non-profit dedicated to promoting the education and well-being of underserved children nationwide, today announced...
March 13, 2025 07:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) ...
March 12, 2025 09:24 ET | Source: Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
March 11, 2025 08:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 37th Annual Roth Conference

FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...